Literature DB >> 27940880

CGRP in human models of primary headaches.

Håkan Ashina1, Henrik Winther Schytz1, Messoud Ashina1.   

Abstract

Objective To review the role of CGRP in human models of primary headaches and to discuss methodological aspects and future directions. Discussion Provocation experiments demonstrated a heterogeneous CGRP migraine response in migraine patients. Conflicting CGRP plasma results in the provocation experiments are likely due to assay variation; therefore, proper validation and standardization of an assay is needed. To what extent CGRP is involved in tension-type headache and cluster headache is unknown. Conclusion Human models of primary headaches have elucidated the role of CGRP in headache pathophysiology and sparked great interest in developing new treatment strategies using CGRP antagonists and antibodies. Future studies applying more refined human experimental models should identify biomarkers of CGRP-induced primary headache and reveal whether CGRP provocation experiments could be used to predict efficacy of CGRP antagonists in migraine patients.

Entities:  

Keywords:  CGRP; human provocation models; migraine; primary headaches

Mesh:

Substances:

Year:  2016        PMID: 27940880     DOI: 10.1177/0333102416684344

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  8 in total

Review 1.  Action mechanisms of Onabotulinum toxin-A: hints for selection of eligible patients.

Authors:  Carlo Lovati; Luca Giani
Journal:  Neurol Sci       Date:  2017-05       Impact factor: 3.307

Review 2.  The association between onabotulinumtoxinA and anti-CGRP monoclonal antibodies: a reliable option for the optimal treatment of chronic migraine.

Authors:  Simona Guerzoni; Carlo Baraldi; Luca Pani
Journal:  Neurol Sci       Date:  2022-06-10       Impact factor: 3.830

Review 3.  Calcitonin gene-related peptide antagonism and cluster headache: an emerging new treatment.

Authors:  Håkan Ashina; Lawrence Newman; Sait Ashina
Journal:  Neurol Sci       Date:  2017-08-30       Impact factor: 3.307

4.  Effects of NSAIDs on the Release of Calcitonin Gene-Related Peptide and Prostaglandin E2 from Rat Trigeminal Ganglia.

Authors:  Vittorio Vellani; Giorgia Moschetti; Silvia Franchi; Chiara Giacomoni; Paola Sacerdote; Giada Amodeo
Journal:  Mediators Inflamm       Date:  2017-10-25       Impact factor: 4.711

5.  Study design for a randomized clinical trial of cognitive-behavioral therapy for posttraumatic headache.

Authors:  Donald D McGeary; Donald B Penzien; Patricia A Resick; Cindy A McGeary; Carlos A Jaramillo; Blessen C Eapen; Stacey Young-McCaughan; Paul S Nabity; John C Moring; Timothy T Houle; Terence M Keane; Alan L Peterson
Journal:  Contemp Clin Trials Commun       Date:  2021-01-06

6.  MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention.

Authors:  Robert Belvís; Pablo Irimia; Patricia Pozo-Rosich; Carmen González-Oria; Antonio Cano; Javier Viguera; Belén Sánchez; Francisco Molina; Isabel Beltrán; Agustín Oterino; Elisa Cuadrado; Angel Gómez-Camello; Miguel Alberte-Woodward; Carmen Jurado; Teresa Oms; David Ezpeleta; Javier Díaz de Terán; Noemí Morollón; Germán Latorre; Marta Torres-Ferrús; Alicia Alpuente; Raquel Lamas; Carlos Toledano; Rogelio Leira; Sonia Santos; Margarita Sánchez Del Río
Journal:  J Headache Pain       Date:  2021-07-17       Impact factor: 7.277

Review 7.  Cross-talk signaling in the trigeminal ganglion: role of neuropeptides and other mediators.

Authors:  Karl Messlinger; Louis K Balcziak; Andrew F Russo
Journal:  J Neural Transm (Vienna)       Date:  2020-02-22       Impact factor: 3.575

8.  The Effect of K ATP Channel Blocker Glibenclamide on CGRP-Induced Headache and Hemodynamic in Healthy Volunteers.

Authors:  Hande Coskun; Fatima Azzahra Elbahi; Mohammad Al-Mahdi Al-Karagholi; Hashmat Ghanizada; Majid Sheykhzade; Messoud Ashina
Journal:  Front Physiol       Date:  2021-06-11       Impact factor: 4.566

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.